AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:27:27 2024-07-10 am EDT			5-day change	1st Jan Change
12,003 ^GBX	+0.49%		-0.15%	+13.23%

01:00pm	ASTRAZENECA : Deutsche Bank reiterates its Neutral rating	ZD
11:10am	Barclays raises Kerry, cuts Hunting, Wood Group	AN

ASTRAZENECA : Deutsche Bank reiterates its Neutral rating

July 10, 2024 at 07:00 am EDT

Deutsche Bank confirms his opinion on the stock and remains Neutral. The target price is unchanged at GBX 11000.

Latest news about AstraZeneca PLC

ASTRAZENECA : Deutsche Bank reiterates its Neutral rating	07:00am	ZD
Barclays raises Kerry, cuts Hunting, Wood Group	05:10am	AN
ASTRAZENECA : JP Morgan reaffirms its Buy rating	02:30am	ZD
AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	Jul. 05	MT
AstraZeneca: cancer treatment approved by the EU	Jul. 05	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	Jul. 05	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	Jul. 05	MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating	Jul. 04	ZD
ASTRAZENECA : Buy rating from Berenberg	Jul. 03	ZD
Aptamer shares jump as inks agreement with AstraZeneca	Jul. 03	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	Jul. 03	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	Jul. 02	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	Jul. 02	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	Jul. 01	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	Jul. 01	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	Jul. 01	MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment	Jul. 01	MT
AstraZeneca applies to the EMA for a Covid antibody	Jul. 01	CF
AstraZeneca: CHMP recommends Imfinzi and Lynparza	Jul. 01	CF
Stocks called higher ahead of Thursday's election	Jul. 01	AN
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application	Jul. 01	MT
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU	Jul. 01	MT
AstraZeneca's COVID prevention drug application gets EU fast-track assessment	Jul. 01	RE
AstraZeneca Plc's Lynparza & Imfinzi Announces Positive CHMP in Endometrial	Jul. 01	CI
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	Jun. 27	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

152.7 USD

Average target price

175.3 USD

Spread / Average Target

+14.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.23%	237B
ELI LILLY AND COMPANY	+59.97%	840B
NOVO NORDISK A/S	+37.86%	621B
JOHNSON & JOHNSON	-6.18%	354B
MERCK & CO., INC.	+15.61%	319B
ABBVIE INC.	+8.44%	297B
NOVARTIS AG	+14.61%	221B
ROCHE HOLDING AG	+0.86%	220B
AMGEN INC.	+9.68%	169B
PFIZER, INC.	-3.72%	157B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Deutsche Bank reiterates its Neutral rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals